Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates

Liver Transplantation

Volumn 19, Issue 3, 2013, Pages 268-274

  Gane, Edward J ^a   Patterson, Scott ^b   Strasser, Simone I ^c   McCaughan, Geoffrey W ^c   Angus, Peter W ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b AUSTIN HEALTH   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; CREATININE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SIDE EFFECT; VIRUS LOAD;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEW SOUTH WALES; NEW ZEALAND; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VICTORIA; VIRAL LOAD; YOUNG ADULT;

EID: 84875164045     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23600     Document Type: Article

References (19)

1. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R,. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157.
2. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE,. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-626.
3. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H,. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
4. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-1364.
5. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003; 38: 86-95.
6. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589.
7. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW,; for Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
8. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E,. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
9. Teperman L, Spivey J, Poordad F, Schiano T, Bzowej N, Pungpapong S, et al. Emtricitabine/tenofovir DF combination +/- HBIG post-orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results [abstract]. J Hepatol 2010; 52 (suppl 1): S12-S13.
10. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology, 2007; 132: 931-937.
11. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
12. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al.; for Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-360.
13. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48: 728-735.
14. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST,. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-813.
15. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219.
16. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
17. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir for chronic hepatitis B: a 5 year open-label follow-up study. Lancet 2013; 381: 468-475.
18. Dan YY, Wai CT, Yeoh KG, Lim SG,. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006; 12: 736-746.
19. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.